Last reviewed · How we verify
Autologous DC vaccine
Autologous DC vaccine is a Cancer vaccine Biologic drug developed by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. It is currently in Phase 2 development for Melanoma.
Stimulates an immune response against cancer cells
Stimulates an immune response against cancer cells Used for Melanoma.
At a glance
| Generic name | Autologous DC vaccine |
|---|---|
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Drug class | Cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Autologous DC vaccines work by stimulating the body's own immune system to recognize and attack cancer cells. Dendritic cells are isolated from the patient, loaded with tumor antigens, and then reinfused to trigger an immune response.
Approved indications
- Melanoma
Common side effects
- Fatigue
- Fever
- Chills
Key clinical trials
- Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE1, PHASE2)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (PHASE1)
- Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (PHASE1)
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML (PHASE1)
- Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma (PHASE2)
- A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma (PHASE1, PHASE2)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous DC vaccine CI brief — competitive landscape report
- Autologous DC vaccine updates RSS · CI watch RSS
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS portfolio CI
Frequently asked questions about Autologous DC vaccine
What is Autologous DC vaccine?
How does Autologous DC vaccine work?
What is Autologous DC vaccine used for?
Who makes Autologous DC vaccine?
What drug class is Autologous DC vaccine in?
What development phase is Autologous DC vaccine in?
What are the side effects of Autologous DC vaccine?
Related
- Drug class: All Cancer vaccine drugs
- Manufacturer: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Melanoma
- Compare: Autologous DC vaccine vs similar drugs
- Pricing: Autologous DC vaccine cost, discount & access